Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Research Program To Focus On Nine Priority Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will prioritize its research efforts on nine disease areas as part of a five-pronged strategy to jumpstart growth

You may also be interested in...



Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity

Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.

Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity

Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.

Merck’s Biotech Pipeline Gets A Boost From Two Acquisitions

Merck will buy the monoclonal antibody developer Abmaxis and yeast glycoengineering specialist GlycoFi.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS061394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel